Merck KGaA (OTCMKTS:MKGAF) Sees Unusually-High Trading Volume – What’s Next?

Merck KGaA (OTCMKTS:MKGAF) saw unusually-high trading volume on Tuesday. Approximately 5,085 shares changed hands during mid-day trading, an increase of 712% from the previous session’s volume of 626 shares. The stock last traded at $162.30 and had previously closed at $155.45.

Merck KGaA Trading Up 5.2%

The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. The company has a market capitalization of $21.14 billion, a P/E ratio of 24.97 and a beta of 0.96. The firm has a fifty day moving average price of $161.19 and a 200-day moving average price of $151.61.

Institutional Investors Weigh In On Merck KGaA

Hedge funds have recently added to or reduced their stakes in the company. Elefante Mark B bought a new stake in Merck KGaA in the 2nd quarter worth approximately $617,000. Ames National Corp purchased a new position in shares of Merck KGaA in the second quarter valued at $1,009,000. Notis McConarty Edward bought a new stake in Merck KGaA in the second quarter worth $1,304,000. North Star Asset Management Inc. purchased a new stake in Merck KGaA during the second quarter valued at $1,411,000. Finally, Pinnacle Holdings LLC bought a new position in Merck KGaA during the second quarter valued at $1,487,000. Institutional investors own 0.10% of the company’s stock.

Merck KGaA Company Profile

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. Merck KGaA is separate from the U.S.-based Merck & Co, Inc, although the two companies share historical roots.

The company operates through three business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, chemicals and bioprocessing technologies used by pharmaceutical, biotechnology and academic customers.